MiNK Therapeutics, Inc.
INKT
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which isā¦ read more
Healthcare
Biotechnology
4 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$12.75
Price-3.56%
-$0.47
1Y
Price
Market Cap
$57.646m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$3.769b
-
1y CAGR-33.3%
3y CAGR-25.0%
5y CAGREarnings
-$2.775b
-25632.5%
1y CAGR-8520.3%
3y CAGR-6388.4%
5y CAGREPS
-$2.87
-2.5%
1y CAGR+25.3%
3y CAGR+21.0%
5y CAGRBook Value
-$25.189m
$2.484m
Assets$27.674m
Liabilities$5.506m
DebtDebt to Assets
221.6%
-0.5x
Debt to EBITDAFree Cash Flow
-$1.347b
-13998.4%
1y CAGR-4647.2%
3y CAGR-3496.9%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company